Laura Hatchman
Family Medicine · Oneida, TNNPI 1427619402
Payments from drug & device makers
Across 128 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$773
- AbbVie$370
- Bayer$247
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$205
- Novo Nordisk$176
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124
- plus $340 from 13 others
What the payments were for
- Food & beverage$2,21399%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $773 |
| AbbVie | 27 | $370 |
| Bayer | 15 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $205 |
| Novo Nordisk | 9 | $176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| AstraZeneca | 4 | $72 |
| Lilly USA, LLC | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $33 |
| Exact Sciences | 2 | $31 |
| Pfizer | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$2,233 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $68,979 |
| BenlystaBelimumab | 13 | $59,082 |
| MounjaroTirzepatide | 39 | $42,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $32,335 |
| VraylarCariprazine Hcl | 20 | $28,715 |
| JanuviaSitagliptin Phosphate | 26 | $25,543 |
| EliquisApixaban | 19 | $22,992 |
| LinzessLinaclotide | 28 | $19,257 |
| JardianceEmpagliflozin | 23 | $16,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $15,345 |
| FarxigaDapagliflozin Propanediol | 19 | $15,268 |
| FlectorDiclofenac Epolamine | 12 | $7,824 |
| TradjentaLinagliptin | 12 | $7,720 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,893 |
| Varenicline Tartrate | 20 | $3,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta, Trelegy Ellipta | $773 | $91,41757 claims |
| Novo NordiskOzempic | $176 | $68,97958 claims |
| AbbVieVraylar, Linzess | $370 | $47,97248 claims |
| Lilly USA, LLCMounjaro | $33 | $42,80639 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $72 | $30,61331 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $16 | $29,78047 claims |
| PfizerEliquis | $27 | $22,99219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Oneida
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.